Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | BRS3 | P32247 | 4/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4303739 | 0.99 | TLR8 (0.36) | TLR8BRS3GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL4297887 | 0.78 | BRS3 (0.42) | BRS3DRD2HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL4066801 | 0.73 | TLR8 (0.37) | TLR8NPC1 | |
| SCHEMBL29113719 | 0.73 | PPARG (0.42) | TLR8NPC1 | |
| SCHEMBL4056960 | 0.72 | PLK1 (0.54) | TRPV1 | |
| SCHEMBL31195411 | 0.72 | PPARG (0.43) | NPC1 | |
| Hydrochloric Acid SCHEMBL4297888 | 0.71 | PLK1 (0.53) | TRPV1 | |
| SCHEMBL1004987 | 0.69 | PPARA (0.53) | — | |
| SCHEMBL11994146 | 0.68 | PPARA (0.48) | TLR8MPLNPC1 | |
| SCHEMBL1002755 | 0.67 | RARB (0.46) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | TLR8 1596/4885BRS3 4220/4885GABRP 642/4885 |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | TLR8 1596/4885BRS3 4220/4885GABRP 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.